PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy.

ABSTRACT:

Background

Immunological checkpoint blockade is effective in treating various malignancies. Identifying predictive biomarkers to assist patient selection for immunotherapy has become a priority in both clinical and research settings.

Methods

Mutations in patients who responded to immunotherapy were identified through next-generation sequencing. Relationships among protein kinase, DNA-activated, catalytic polypeptide (PRKDC) mutations, mutation load and microsatellite instability (MSI) were analyzed using datasets from The Cancer Genome Atlas. These relationships were validated by conducting an in vitro study and by using tissue samples from 34 patients with gastric cancer. The CT26 animal model was used to evaluate the role of PRKDC as a predictive biomarker and the e

SUBMITTER: Tan KT 

PROVIDER: S-EPMC7174075 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature